Every S-1 that Ernexa Therapeutics Inc. (ERNA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow ERNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERNA filings page.
Ernexa Therapeutics Inc. is registering up to 13,586,956 shares of common stock, associated pre-funded warrants and common warrants, plus up to 203,804 Agent’s Shares, in a primary, best-efforts offering with no minimum amount required to close.
Each common share is sold together with a common warrant to buy one additional share, at a combined price assumed at $0.92, the February 3, 2026 Nasdaq closing price. Certain large investors may instead buy pre-funded warrants priced $0.005 below the share price, with a $0.005 exercise price and no expiration until fully exercised.
The common warrants will be immediately exercisable, with an exercise price set at the Nasdaq closing price at pricing, and will expire on the earlier of five years from issuance or 180 days after public release of first-cohort Phase 1 data for ERNA-101. Common stock trades on Nasdaq as “ERNA,” and Ernexa has applied to list the common warrants as “ERNAW.”
The company highlights significant ongoing losses, a large accumulated deficit and a need for substantial additional capital, warning it may not be able to continue as a going concern without new funding. It also discloses heavy reliance on licensed intellectual property from Factor Bioscience and outlines extensive business, technology, regulatory, and offering-related risks, including potentially significant dilution and the absence of any dividend plan.
Ernexa Therapeutics Inc. is seeking to raise up to $12,500,000 through a best-efforts public offering of common stock and common warrants, with Brookline Capital Markets acting as exclusive placement agent. Each share is sold with a warrant to buy one additional share, and the warrants are expected to list on Nasdaq as “ERNAW.”
The company is a preclinical-stage developer of synthetic iMSC cell therapies, led by ERNA-101 for platinum-resistant ovarian cancer, with an IND filing targeted in 2026 and a Phase 1 trial planned thereafter. Ernexa recently increased its authorized common stock to 150 million shares, executed a 1-for-15 reverse split, and raised about $7.2 million in a prior private placement, yet still warns it will require substantial additional capital and faces going-concern, regulatory, competition, intellectual property, and Nasdaq listing risks.
Ernexa Therapeutics Inc. has filed an S-1 for a primary, best-efforts offering of common stock paired with tradable common warrants, with Brookline Capital Markets acting as exclusive placement agent. The company will also issue “Agent’s Shares” equal to 1.5% of shares sold (0.5% for certain existing investors).
The warrants are immediately exercisable at a price based on the Nasdaq closing price at pricing and will expire on the earlier of five years from issuance or 180 days after public release of first-cohort Phase 1 ERNA-101 data. Ernexa is a preclinical synthetic iMSC cell-therapy company focused on ERNA-101 in platinum-resistant ovarian cancer and ERNA-201 for autoimmune disease.
Recent actions include increasing authorized common stock to 150 million shares, a 1-for-15 reverse split, and a $7.2 million 2025 private placement. As of January 27, 2026, 7,853,538 common shares were outstanding. The risk section highlights substantial additional capital needs, going concern risk, dependence on licensed IP, intense competition, and potential Nasdaq listing and dilution risks.